Positron emission tomography (PET) combined with the tracer florbetapir F 18 showed significant differences in beta-amyloid burden in the brains of patients with probable Alzheimer’s disease, mild cognitive impairment, and healthy older adults, according to a new study.
Positron emission tomography (PET) combined with the tracer florbetapir F 18 showed significant differences in beta-amyloid burden in the brains of patients with probable Alzheimer’s disease, mild cognitive impairment, and healthy older adults, according to a new study published online this week in the Archives of Neurology.
The researchers, led by Adam S. Fleischer of the Banner Alzheimer’s Consortium in Phoenix, Ariz., say radiologists using florbetapir PET could thereby help diagnose Alzheimer’s disease as well as the amyloid levels of patients at risk of the disease.
Beta-amyloid is considered a key player in Alzheimer’s disease, which the Alzheimer’s Association estimates to affect 5.4 million Americans.
The study involved 68 participants with probably Alzheimer’s disease, 60 with mild cognitive impairment, and 82 healthy adults aged 55 and older. The researchers considered cerebral-to-whole-cerebellar standard uptake value ratios (SUVRs) for the three groups, and then compared mean cortical SUVRs. An SUVR greater than or equal to 1.17 reflected beta-amyloid levels of Alzheimer’s disease. A separate set of 19 Alzheimer’s patients who underwent PET and postmortem examinations had established this. Similarly, a threshold SUVR of 1.08 was used to establish the presence of beta-amyloid based on a separate set of 46 individuals 18 to 40 years of age.
Patients with Alzheimer’s disease had mean cortical florbetapir SUVRs of 1.39; those with mild cognitive impairment were at 1.17, and the control group registered 1.05. On a percentage basis, 80.9 percent of the suspected Alzheimer’s group met the amyloid threshold associated with Alzheimer’s disease, with 46.6 percent of those with mild cognitive impairment and 28.1 percent of the control group reaching those amyloid levels.
The authors said their study confirms the ability of florbetapir PET to characterize amyloid levels in probably Alzheimer’s disease patients, those with mild cognitive impairment, and healthy adults.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.